Where this chronic lymphocytic leukaemia information comes from
On this page are the major sources of information that we use to put together this section.
All our information is checked by cancer specialists and surgeons who specialise in treating cancer. The names of our specialist reviewers are at the end of this list. We also try to find patients to review all our sections. If you have had chronic lymphocytic leukaemia, live in the UK, and would like to become a patient reviewer, you can write to us by clicking on contact us.
Cancer Research UK
US National Cancer Institute
Information on the treatment of chronic lymphocytic leukaemia
Leukaemia and Lymphoma Research
Information about chronic lymphocytic leukaemia
Principles and practice of oncology (10th edition)
De Vita VT, Hellman S and Rosenberg SA.
Lippincott, Williams and Wilkins, 2015
Cancer and its management (6th edition)
Souhami R and Tobias J
National Institute for Health and Care Excellence guidance
Bendamustine for chronic lymphocytic leukaemia Binet stage B and C for people who cannot have fludarabine, February 2011– link to guidance
Ofatumumab for the treatment of chronic lymphocytic leukaemia refractory to fludarabine and alemtuzumab, October 2010 – link to guidance
Rituximab for first line chronic lymphocytic leukaemia, July 2009 – link to rituximab for CLL guidance
Fludarabine monotherapy for the first-line treatment of chronic lymphocytic leukaemia, February 2007 – link to fludarabine for CLL guidance
Referral for suspected cancer. A clinical practice guideline, June 2015 – link to the referral guidelines on the NICE website
Improving outcomes in haematological cancers, October 2003 – link to NICE haematological cancers manual
Scottish Medicines Consortium guidelines
Bendamustine for chronic lymphocytic leukaemia Binet stage B and C for people who cannot have fludarabine, April 2011– link to guidance
Ofatumumab for the treatment of chronic lymphocytic leukaemia refractory to fludarabine and alemtuzumab, August 2010 – link to SMC website
Chronic lymphocytic leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow up. Eichorst B and others. Annals of Oncology 22 (Supplement 6): vi50-vi54, 2011
State of the art treatment of chronic lymphocytic leukaemia. Hallek M and Pflug N. Blood Reviews, 2011 No 25.
Rituximab Plus Fludarabine and Cyclophosphamide Prolongs Progression-Free Survival Compared With Fludarabine and Cyclophosphamide Alone in Previously Treated Chronic Lymphocytic Leukemia. Robak T and others. Journal of Clinical Oncology, 2010 Vol 28 No 10.
Ofatumumab for fludarabine refractory chronic lymphocytic leukaemia – second or third line. UK National Horizon Scanning Centre Health Technology Assessment (HTA) Database, 19 May 2010.
Activity of the cyclin dependent kinase (CDK) inhibitor flavopiridol in relapsed, genetically high risk chronic lymphocytic leukemia (CLL). Lin T and others. Journal of Clinical Oncology 2008; 26:373s.
Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Catovsky D and others on behalf of the UK National Cancer Research Institute (NCRI) Haematological Oncology Clinical Studies Group and NCRI Chronic Lymphocytic Leukaemia Working Group, 2007. The Lancet, 370, 230-39.
Purine Antagonists for Chronic Lymphocytic Leukaemia. Steurer M and others (Cochrane review). Cochrane Database of Systematic Reviews, 2007, Issue 3, Art. No: CD004270. DOI:10.1002/14651858.
Emerging therapy for chronic lymphocytic leukaemia. Auer RL and others. British Journal of Haematology, 2007;139:635-644.
Dr Nilima Parry-Jones
Dr Prem Mahendra
Dee McLean – McDee Art, Medical Illustrations
Question about cancer? Contact our information nurse team